GUERF: AI 评分 43/100 — AI 分析 (4月 2026)

Guerbet S.A. develops and markets contrast media, delivery systems, and medical devices. The company's products are used in medical imaging for diagnosis and treatment across various therapeutic areas.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Guerbet S.A., founded in 1926, is a global leader in contrast agents and medical solutions for diagnostic and interventional imaging. The company offers a comprehensive portfolio of products and services for MRI, CT, and interventional radiology, with a focus on innovation and patient safety in the healthcare sector.

GUERF是做什么的？

Founded in 1926 and headquartered in Villepinte, France, Guerbet S.A. has evolved into a key player in the medical imaging field. The company specializes in developing and marketing contrast media, delivery systems, medical devices, and related solutions. Guerbet's initial focus was on the development of Lipiodol, an iodinated poppyseed oil used in radiology. Over the decades, Guerbet expanded its product portfolio to include a range of contrast agents for various imaging modalities, including MRI, CT, and X-ray. Key products include Optiray and Xenetix, non-ionic iodinated contrast agents used in CT scans, and Dotarem, a gadolinium-based contrast agent for MRI. The company also offers digital solutions like Contrast&Care and Dose&Care to improve injection management and dose optimization. Guerbet's interventional radiology products include Lipiodol and Vectorio, used in trans-arterial chemoembolization (TACE) for liver cancer treatment. Guerbet operates globally, with a presence in Europe, the Americas, and Asia. The company competes with major players in the contrast media market, focusing on innovation and strategic partnerships to maintain its market position.

GUERF的投资论点是什么？

Guerbet S.A. presents a mixed investment case. Its established position in the contrast media market and diversified product portfolio provide a stable revenue base. The company's focus on digital solutions and interventional radiology offers growth opportunities. However, the negative profit margin of -14.2% and a P/E ratio of -0.95 raise concerns about profitability. The company's beta of 0.69 suggests lower volatility compared to the market. Upcoming catalysts include potential regulatory approvals for new products and expansion into emerging markets. Investors should monitor the company's ability to improve profitability and manage its debt levels.

GUERF在哪个行业运营？

Guerbet S.A. operates in the medical instruments and supplies industry, which is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced imaging solutions. The global contrast media market is expected to grow, driven by the rising prevalence of chronic diseases and the increasing adoption of diagnostic imaging procedures. Guerbet competes with larger players in the market, such as BTMD, CSSPF, DLHTF, HTLZF, and NWPHF, focusing on niche markets and specialized products to differentiate itself.

Medical - Instruments & Supplies

Healthcare

GUERF有哪些增长机遇？

Expansion of Digital Solutions: Guerbet's digital solutions, such as Contrast&Care and Dose&Care, offer significant growth potential. The market for digital healthcare solutions is expanding rapidly, driven by the need for improved efficiency and patient outcomes. By leveraging its expertise in contrast media and imaging, Guerbet can develop innovative digital tools that integrate seamlessly with existing workflows. The global market for healthcare IT solutions is projected to reach $390 billion by 2027, providing a substantial opportunity for Guerbet to increase its market share.
Growth in Interventional Radiology: Guerbet's interventional radiology products, including Lipiodol and Vectorio, target a growing market driven by minimally invasive procedures. The increasing prevalence of liver cancer and other chronic diseases is driving demand for TACE and other interventional treatments. Guerbet's focus on innovative delivery systems and specialized products positions it well to capitalize on this trend. The interventional radiology market is expected to reach $35 billion by 2028, offering a significant growth opportunity for Guerbet.
Geographic Expansion in Emerging Markets: Guerbet has the opportunity to expand its presence in emerging markets, where demand for diagnostic imaging is growing rapidly. These markets offer significant potential for increased sales of contrast media and related products. By establishing strategic partnerships and tailoring its product offerings to local needs, Guerbet can gain a foothold in these markets and drive long-term growth. The emerging markets healthcare sector is projected to grow at a rate of 8-10% annually over the next five years.
New Product Development and Innovation: Guerbet can drive growth through continuous innovation and the development of new contrast agents and delivery systems. By investing in research and development, the company can introduce novel products that address unmet clinical needs and improve patient outcomes. This includes developing contrast agents with improved safety profiles and enhanced imaging capabilities. The pharmaceutical and medical device industries rely heavily on innovation, and Guerbet's commitment to R&D is crucial for maintaining its competitive edge.
Strategic Partnerships and Acquisitions: Guerbet can pursue strategic partnerships and acquisitions to expand its product portfolio and geographic reach. By collaborating with other companies in the medical imaging field, Guerbet can gain access to new technologies and markets. Acquisitions can also provide opportunities to consolidate the market and increase market share. The healthcare industry is characterized by frequent mergers and acquisitions, and Guerbet can leverage these opportunities to accelerate its growth.

Market capitalization of $0.28 billion indicates a relatively small-cap company.
Negative P/E ratio of -0.95 reflects current losses, requiring careful monitoring of profitability trends.
Gross margin of 2.4% is significantly lower than industry averages, suggesting potential cost management issues.
Beta of 0.69 indicates lower volatility compared to the overall market, potentially offering stability during market downturns.
Dividend yield of 0% indicates that the company does not currently distribute profits to shareholders.

GUERF提供哪些产品和服务？

Develops and markets contrast media products for medical imaging.
Offers delivery systems for contrast agents used in MRI, CT, and X-ray.
Provides medical devices and related solutions for diagnostic and interventional imaging.
Offers contrast agents like Optiray and Xenetix for CT scans.
Provides Dotarem, a gadolinium-based contrast agent for MRI.
Offers digital solutions like Contrast&Care and Dose&Care for injection management and dose optimization.
Provides products for interventional radiology, including Lipiodol and Vectorio.

GUERF如何赚钱？

Develops and manufactures contrast media products.
Sells contrast media and delivery systems to hospitals and imaging centers.
Offers digital solutions and services to healthcare providers.
Generates revenue through product sales and service contracts.

Hospitals and clinics
Radiology and imaging centers
Interventional radiology specialists
Healthcare professionals

Established brand reputation in the contrast media market.
Specialized expertise in contrast agent development and delivery systems.
Proprietary technologies and intellectual property.
Strong relationships with healthcare providers.

什么因素可能推动GUERF股价上涨？

Upcoming: Potential regulatory approvals for new contrast agents.
Upcoming: Expansion into emerging markets in Asia and Latin America.
Ongoing: Increasing demand for diagnostic imaging procedures.
Ongoing: Development of new digital solutions for healthcare providers.

GUERF的主要风险是什么？

Potential: Intense competition from larger players in the contrast media market.
Potential: Pricing pressures and reimbursement challenges.
Potential: Regulatory changes and compliance requirements.
Ongoing: Product liability risks associated with medical devices.
Ongoing: Negative profit margin and low gross margin.

GUERF的核心优势是什么？

Established presence in the contrast media market.
Diversified product portfolio across imaging modalities.
Focus on innovation and digital solutions.
Global presence with operations in key markets.

GUERF的劣势是什么？

Negative profit margin and low gross margin.
High debt levels.
Dependence on regulatory approvals for new products.
Limited market share compared to larger competitors.

GUERF有哪些机遇？

Expansion in emerging markets.
Growth in interventional radiology.
Development of new contrast agents and delivery systems.
Strategic partnerships and acquisitions.

GUERF面临哪些威胁？

Intense competition from larger players.
Pricing pressures and reimbursement challenges.
Regulatory changes and compliance requirements.
Product liability risks.

GUERF的竞争对手是谁？

Biotronik SE & Co. KG — Focuses on cardiovascular medical technology. — (BTMD)
Canon Medical Systems Corp — Offers a broad range of medical imaging solutions. — (CSSPF)
DiaSorin SpA — Specializes in in-vitro diagnostics. — (DLHTF)
Hologic Inc — Focuses on women's health and diagnostics. — (HTLZF)
Nipro Corp — Offers a diverse range of medical devices and pharmaceuticals. — (NWPHF)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: David Hale
Headquarters: Villepinte, FR
Employees: 2,839
Founded: 2017

AI Insight

AI analysis pending for GUERF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Guerbet S.A. do?

Guerbet S.A. specializes in developing and marketing contrast media, delivery systems, medical devices, and related solutions for diagnostic and interventional imaging. The company's products are used in MRI, CT, and X-ray procedures to enhance the visibility of internal organs and tissues. Guerbet's offerings include contrast agents, injectors, and digital solutions designed to improve patient outcomes and streamline workflows for healthcare providers. The company operates globally, serving hospitals, clinics, and imaging centers.

What do analysts say about GUERF stock?

Analyst coverage of GUERF stock is limited due to its OTC listing. Key valuation metrics, such as the negative P/E ratio, reflect current losses. Growth considerations include the company's expansion into digital solutions and emerging markets. Investors should carefully monitor the company's financial performance and competitive landscape. There is no consensus rating available due to the limited coverage.

What are the main risks for GUERF?

The main risks for GUERF include intense competition from larger players in the contrast media market, pricing pressures and reimbursement challenges, regulatory changes and compliance requirements, and product liability risks associated with medical devices. The company's negative profit margin and low gross margin also pose significant financial risks. Additionally, the OTC listing introduces risks related to liquidity, transparency, and regulatory oversight.

What revenue streams does Guerbet S.A. have in healthcare?

Guerbet S.A.'s revenue streams are primarily derived from the sale of contrast media products across various imaging modalities, including MRI, CT, and X-ray. Additional revenue is generated from the sale of delivery systems, medical devices, and digital solutions. The company's revenue is also segmented by geographic market, with a significant portion coming from Europe, the Americas, and Asia. The specific breakdown of revenue by product line, therapeutic area, and geographic market is not publicly available.

How does Guerbet S.A. manage its supply chain?

Guerbet S.A. manages its supply chain by sourcing raw materials and components from various suppliers globally. The company has established quality control processes to ensure the safety and efficacy of its products. Guerbet also works closely with its suppliers to optimize costs and minimize disruptions. The company's supply chain is subject to regulatory requirements and compliance standards, which are closely monitored to ensure adherence.